GS71.DE Forex ziņas

Shares of Nuvalent, Inc. were surging around 39 percent in the pre-market activity on the Nasdaq, after the clinical-stage biopharma company focused on cancer therapies agreed to be acquired by British drug major GSK plc, in a deal valued at $10.6 billion or 8.0 billion pounds. Further, GSK maintained its 2026 guidance range of 7 percent to 9 percent growth in core operating profit and core EPS.